RECRUITING

Molecular Genetics Studies of Cancer Patients and Their Relatives

Talk to us

Conditions

Malignant Neoplasm

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This trial studies the genetic and behavioral factors that may contribute to the development of specific cancers and how these factors may affect the outcome of the disease in patients with a history of cancer and their relatives.

Official Title

Molecular Genetics Studies of Cancer Patients and Their Relatives

Quick Facts

Study Start:1997-04-18
Study Completion:2033-08-18
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04185935

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Individuals must have a personal history of cancer and/or a family history of cancer suggestive of the presence of an inherited predisposition. This inherited predisposition might manifest as:
  2. * Young age cancer diagnosis
  3. * Multiple primary neoplasms in affected member
  4. * The presence of rare tumor types in the family
  5. * Congenital malformations
  6. * Any other family clustering of cancer
  7. * Any other cancer-predisposing genetic diseases/conditions
  8. * Individuals may also be eligible by participation in the City of Hope Cancer Screening \& Prevention Program Network (CSPPN) clinical service or on the basis of membership in a group known or suspected to have an increased risk of carrying a genetic alteration or of sustaining a particular exposure that would place that at increased risk of cancer. (Examples would include members of occupational cohorts like asbestos workers, individuals with multiple dysplastic nevi in the absence of a family history of cancer, and individuals descended from a particular tribe in the American Southwest who have an increased incidence of a rare genetic alteration associated with an increased risk of a specific cancer.)
  9. * Individuals and families may be referred to us in a number of different ways. After initial contact is made with a individual or family by family studies personnel; an individual within the bloodline will be identified as the historian. There may be more than one historian within a family
  10. * At least one historian must be wiling to provide information or access as needed to contact appropriate family members for documentation of cancer and for consent. An individual is considered to be eligible to participate if they criteria; contact with relatives is not always indicated
  11. * Individuals who are under 18 are eligible for study if they meet the criteria. Consent for participation must be given by a legal guardian or parent
  12. * Deceased patients may be included in the study. Public records, such as death certificates, can be used to confirm information from individuals or family members. If medical records are needed, consent for these records will be obtained from the deceased's next of kin. Next of kin refers to the following hierarchy of relatives; spouse, offspring, parents, and siblings. (Any further use of next of kin in this protocol should relate back to this hierarchy.) Archived tissue samples, such as pathology blocks or snap frozen tumor from a pathology department tumor bank (discard specimens) may be used for genetic research
  1. * A family may be ineligible for study if the historian will not allow access to anyone within the family and thus, the accuracy of the family history cannot be established

Contacts and Locations

Study Contact

Stephen Gruber
CONTACT
sgruber@coh.org

Principal Investigator

Stephen Gruber, MD
PRINCIPAL_INVESTIGATOR
City of Hope Medical Center

Study Locations (Sites)

Valleywise Comprehensive Health Center - Phoenix
Phoenix, Arizona, 85008
United States
John Muir Medical Center-Concord Campus
Concord, California, 94520
United States
City of Hope Medical Center
Duarte, California, 91010
United States
Saint Jude Medical Center
Fullerton, California, 92835
United States
Saddleback Memorial Medical Center
Laguna Hills, California, 92653
United States
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033
United States
Saint Joseph Hospital - Orange
Orange, California, 92868
United States
Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California, 95661
United States
Cancer Center of Santa Barbara
Santa Barbara, California, 93105
United States
Lynn Regional Cancer Center - West
Boca Raton, Florida, 33428
United States
Holy Cross Hospital
Fort Lauderdale, Florida, 33308
United States
Kootenai Cancer Center
Post Falls, Idaho, 83854
United States
John H Stroger Jr Hospital of Cook County
Chicago, Illinois, 60612
United States
Rush University Medical Center
Chicago, Illinois, 60612
United States
Mercy Hospital
Cedar Rapids, Iowa, 52403
United States
Suburban Hospital
Bethesda, Maryland, 20814
United States
Frederick Oncology Hematology Associates
Frederick, Maryland, 21702
United States
Steward Saint Elizabeth's Medical Center
Brighton, Massachusetts, 02135
United States
Hunterdon Medical Center
Flemington, New Jersey, 08822
United States
Lovelace Medical Center-Downtown
Albuquerque, New Mexico, 87102
United States
New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico, 87109
United States
Presbyterian Kaseman Hospital
Albuquerque, New Mexico, 87110
United States
Mount Kisco Medical Group at Northern Westchester Hospital
Mount Kisco, New York, 10549-3417
United States
Health Quest Medical Practice PC-Cardio Thoracic
Poughkeepsie, New York, 12601
United States
Aultman Health Foundation
Canton, Ohio, 44710
United States
Saint Charles Health System
Bend, Oregon, 97701
United States
Paoli Memorial Hospital
Paoli, Pennsylvania, 19301
United States
Reading Hospital
West Reading, Pennsylvania, 19611
United States
The Don and Sybil Harrington Cancer Center
Amarillo, Texas, 79106
United States
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, Texas, 77030
United States
Doctor's Hospital of Laredo
Laredo, Texas, 78041
United States
Covenant Medical Center
Lubbock, Texas, 79410
United States
Saint Agnes Hospital/Agnesian Cancer Center
Fond Du Lac, Wisconsin, 54935
United States
ProHealth Waukesha Memorial Hospital
Waukesha, Wisconsin, 53188
United States
Cheyenne Regional Medical Center-West
Cheyenne, Wyoming, 82001
United States

Collaborators and Investigators

Sponsor: City of Hope Medical Center

  • Stephen Gruber, MD, PRINCIPAL_INVESTIGATOR, City of Hope Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date1997-04-18
Study Completion Date2033-08-18

Study Record Updates

Study Start Date1997-04-18
Study Completion Date2033-08-18

Terms related to this study

Additional Relevant MeSH Terms

  • Malignant Neoplasm